Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) EV-to-EBIT : -14.81 (As of Apr. 26, 2024)

Biohaven Pharmaceutical Holding Co EV-to-EBIT Chart

Biohaven Pharmaceutical Holding Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EV-to-EBIT	Get a 7-Day Free Trial															-8.27	-12.59	-13.46	-15.93	-14.11

Competitive Comparison of Biohaven Pharmaceutical Holding Co's EV-to-EBIT

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohaven Pharmaceutical Holding Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's EV-to-EBIT falls into.

Biohaven Pharmaceutical Holding Co EV-to-EBIT Calculation

Biohaven Pharmaceutical Holding Co's EV-to-EBIT for today is calculated as:

Biohaven Pharmaceutical Holding Co's current Enterprise Value is $11,087.2 Mil.
Biohaven Pharmaceutical Holding Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-748.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biohaven Pharmaceutical Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Biohaven Pharmaceutical Holding Co's Enterprise Value for the quarter that ended in Jun. 2022 was $10,568.5 Mil.
Biohaven Pharmaceutical Holding Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-748.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohaven Pharmaceutical Holding Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description